Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-3.12 Insider Own0.10% Shs Outstand356.40M Perf Week1.03%
Market Cap85.32B Forward P/E13.41 EPS next Y17.86 Insider Trans-15.19% Shs Float334.72M Perf Month-2.44%
Income-1219.50M PEG- EPS next Q3.36 Inst Own93.10% Short Float2.55% Perf Quarter23.75%
Sales14.57B P/S5.86 EPS this Y63.30% Inst Trans-6.83% Short Ratio2.38 Perf Half Y-1.59%
Book/sh199.95 P/B1.20 EPS next Y11.34% ROA10.90% Target Price268.50 Perf Year-13.02%
Cash/sh37.11 P/C6.45 EPS next 5Y13.81% ROE19.60% 52W Range183.98 - 279.19 Perf YTD14.31%
Dividend2.80 P/FCF104.87 EPS past 5Y-28.70% ROI0.10% 52W High-14.26% Beta1.12
Dividend %1.17% Quick Ratio2.20 Sales past 5Y26.00% Gross Margin87.20% 52W Low30.11% ATR3.54
Employees16700 Current Ratio2.30 Sales Q/Q7.10% Oper. Margin-12.50% RSI (14)58.35 Volatility1.73% 1.44%
OptionableYes Debt/Eq0.47 EPS Q/Q85.60% Profit Margin- Rel Volume0.70 Prev Close237.33
ShortableYes LT Debt/Eq0.42 EarningsFeb 08 BMO Payout0.00% Avg Volume3.59M Price239.38
Recom2.00 SMA20-0.37% SMA502.39% SMA2005.08% Volume2,514,100 Change0.86%
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Oct-31-16Resumed Barclays Equal Weight $250
Oct-11-16Reiterated Mizuho Buy $305 → $299
Aug-19-16Upgrade Mizuho Neutral → Buy $248 → $318
Aug-09-16Reiterated RBC Capital Mkts Outperform $307 → $300
Aug-09-16Reiterated Deutsche Bank Buy $282 → $278
Aug-05-16Reiterated Mizuho Neutral $232 → $246
Jul-27-16Reiterated Leerink Partners Outperform $272 → $294
Jul-25-16Initiated Credit Suisse Outperform $327
May-13-16Reiterated Mizuho Neutral $250 → $232
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
Apr-07-16Resumed JP Morgan Overweight
Apr-07-16Reiterated UBS Buy $366 → $300
Mar-27-17 07:00PM  Risk-Reward With Teva Pharmaceutical
06:00PM  Why Impax Labs Soared 37.3% Today at Motley Fool
05:46PM  Health care showdown: Allergan vs. Valeant
05:05PM  DuPont, Impax Labs gain, G-III Apparel slides
01:20PM  Has Allergan's Pullback Ended?
12:41PM  Why Moat Indexes Outperformed Others in February
11:34AM  Allergan, Parateks Acne Drug Succeeds in Phase 3 at Investopedia
11:20AM  Paratek eyes FDA filing as acne drug clears late-stage trials at
11:20AM  Foamix Acne Drug Fails Late-Stage Study at Investopedia
09:28AM  Skincare Makers Lead Biotech Movers
07:48AM  Allergan, Paratek Pharma report positive results in late-stage trial of acne treatment at MarketWatch
07:36AM  Vyzulta May Be a Potent Therapy for Glaucoma in the Future
07:31AM  Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne PR Newswire
07:30AM  Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne GlobeNewswire
Mar-26-17 11:01AM  3 Great Stocks to Buy in a Market Pullback at Motley Fool
Mar-24-17 02:00PM  Can Anyone Challenge Allergan In Medical-Aesthetics Market?
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
01:00AM  After Trump rally, equity investors move into healthcare, retailers Reuters
Mar-23-17 06:31PM  The Most Attractive Value Stock There Is?
11:24AM  Insys Therapeutics' Syndros Gets Final DEA Rule at Investopedia
10:19AM  Allergan's Restasis Now Available in Multidose Bottle in U.S.
09:20AM  Buyback ETF Steady As Repurchases Decline
09:06AM  Teva Denies Reports About 11% Global Workforce Reduction (TEVA) at Investopedia
08:59AM  The Supreme Court could fundamentally change America's broken patent system
Mar-22-17 06:45PM  Companies Spend Less on Share Buybacks for Second Year in 2016
04:35PM  Allergan, Dow's Apple Lead Q4 Buybacks; Health Care Atop S&P 500
02:52PM  Allergan Stock Reacts Well In Downtrodden Sector at Investopedia
10:30AM  Latest Editas research pact could be worth up to $1 billion at
07:31AM  Allergan Announces Availability of RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle PR Newswire
Mar-21-17 05:35PM  David Tepper Takes Big Risks for Big Rewards
05:26PM  FDA Links Breast Implants To A Rare Form Of Cancer
02:58PM  Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
Mar-20-17 04:51PM  Editas Get A Vetr Upgrade To Strong Buy
01:53PM  Allergan Is Setting Up Nicely for a Possible Move at Investopedia
07:31AM  JUVÉDERM VOLLURE XC Approved by U.S. FDA for Correction of Facial Wrinkles and Folds in Adults over the Age of 21 PR Newswire
Mar-17-17 09:27AM  Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
Mar-16-17 03:36PM  Valeant: Yes, Ackman's a Loser. But How Much Did Short Sellers Make? at
12:35PM  Court allows Allergan shareholders to go after Ackman, Valeant as a class at
06:11AM  When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)
Mar-15-17 07:15PM  How to maneuver CEO buybacks
06:53PM  Cramer on how investors should maneuver CEO buybacks
06:35PM  Cramer on how investors should maneuver amid CEO buybacks at CNBC
05:46PM  Allergan (AGN) and Editas Tie Up to Treat Eye Diseases
10:37AM  David Tepper on Allergan: Does It Look Cheap?
Mar-14-17 05:24PM  Here's Why Editas Medicine Gained as Much as 17.2% Today at Motley Fool
04:30PM  Allergan plc and Editas Medicine Inc Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases Call scheduled for 4:30 pm ET today
04:19PM  Common explains why he's fighting against a blindness epidemic most people don't know about
03:05PM  Pfizer Unveils Zavicefta Antibiotic in Germany, UK at Investopedia
02:03PM  Ackman's winners & losers
01:48PM  Bill Ackman Is Done Losing Money on Valeant
01:12PM  Ackman's minus touch
11:25AM  CRISPR Could Change The World, But Right Now $90 Million Is Enough at Forbes
11:15AM  Allergan, Editas In Gene-Editing Eye Disease Pact at Investopedia
09:59AM  Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases
09:26AM  Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira
09:17AM  New Survey Reveals Impact Of Double Chin On Self-Perception And Behavior PR Newswire
09:10AM  Award Winning Actor And Hip-Hop Artist Common Joins Allergan's See America(SM) Initiative To Further The Fight Against Preventable Blindness PR Newswire
09:00AM  Editas bags $90M in gene editing R&D pact with Allergan at
08:35AM  Editas Medicine surges 8% on $90 million Allergan research and development deal at MarketWatch
08:22AM  Allergan signs deal with Editas for gene-editing-based eye treatments
08:00AM  Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases PR Newswire
08:00AM  Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases GlobeNewswire
12:02AM  [$$] William Ackmans Pershing Square Sold Stake in Valeant at The Wall Street Journal
Mar-13-17 09:59PM  [$$] Pershing Square Sold Stake in Valeant at The Wall Street Journal
06:25PM  Food And Drug Administration Accepts Allergan PLC (AGN) Vraylar For Review As A Supplemental Drug at Insider Monkey
04:25PM  Lilly, Merck, Allergan Top Analyst's View For 2017 Pharma
11:18AM  Billionaire David Tepper Makes Huge Investments In These 4 Drug Stocks at Insider Monkey
09:40AM  Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
01:00AM  Google, Apple, Starbucks: Doug Kass' Views
01:00AM  Allergan, Schlumberger, Caterpillar: Doug Kass' Views
Mar-10-17 05:57PM  Trump nominates FDA head with deep ties to drug companies Reuters
01:20PM  And the winner is? Who took home life sciences industry awards last night at
10:28AM  Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
Mar-09-17 02:00PM  Allergan plc Question if a Feminist Can Love Fillers? PR Newswire
10:55AM  Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA
Mar-08-17 04:13PM  Battered Biotech Teva Is a Smart Contrarian Buy Now
04:08PM  David Tepper Discusses Allergan Investment, Market Valuation
01:52PM  The Tepper blitz on The Halftime Report
09:27AM  Hedge Fund Guru Tepper Bullish on Allergan at Investopedia
08:00AM  FDA Accepts Supplemental New Drug Application (sNDA) For VRAYLAR (cariprazine) PR Newswire
07:50AM  David Tepper's big bet in pharma
07:25AM  Are Hedge Funds Turning Bearish on Healthcare Stocks? at Insider Monkey
06:24AM  Logitech: Cramer's Top Takeaways
06:15AM  Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)
Mar-07-17 03:30PM  Fred's adds three industry veterans to board at
12:38PM  Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan
Mar-06-17 02:35PM  Jeff Auxier Invests in Gilead, Wells Fargo, Apple
Mar-05-17 07:22AM  Billionaires Love These 3 Healthcare Stocks at Motley Fool
Mar-04-17 07:25PM  Icahn's (Potential) Move Into Biotech
Mar-03-17 07:13PM  FDA approves first drug to limit frequent waking to urinate
04:05PM  Allergan Presents Data From 21 Abstracts At The 2017 American Academy Of Dermatology Meeting In Orlando, FL PR Newswire
Mar-02-17 02:11PM  The Best Dividend Investors Are Preparing For Higher Interest Rates at Forbes
01:04PM  ALLERGAN PLC Financials
09:59AM  The eyes have it in Allergan's new ad campaign from FCB Chicago at
08:00AM  Allergan to Present at the Barclays Global Healthcare Conference PR Newswire
Mar-01-17 06:58PM  Cramer Remix: Investors are too negative about fast-growi...
06:47PM  Could pharma sector roar even higher? Cramer checks the c...
06:42PM  Cramers charts uncover 4 pharma stocks ready to explode ...
06:36PM  Cramers charts uncover 4 pharma stocks ready to explode higher at CNBC
06:08PM  Jerome Dodson Adds to 9 Positions in 4th Quarter
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISARO PAULDirectorMar 02Sale246.6870,00017,267,561235,900Mar 06 06:59 AM
Meury WilliamChief Commercial OfficerDec 08Option Exercise109.1211,8071,288,38048,866Feb 14 09:13 PM
Basgoz NesliDirectorDec 08Sale188.7250094,3605,515Dec 09 05:56 PM
SAUNDERS BRENT LCEO and PresidentNov 21Buy189.135,250992,941106,564Nov 21 04:03 PM
Hilado Maria TeresaChief Financial OfficerNov 11Buy210.641,422299,53613,379Nov 15 05:18 PM